Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

ITM Radiopharma’s Phase III trial of its targeted radiotherapeutic for patients with Grade 1 or 2 gastroenteropancreatic ...

AB2 Bio has made an option and licensing agreement with Nippon Shinyaku, granting the latter the option to commercialise ...

Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.

Arena International’s Outsourcing in Clinical Trials West Coast 2025 will discuss patient centricity, diversity, and ...

This study reinforces the significance of intensive glycaemic control and is a paradigm shift in managing the disease and its ...

Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for use as an anti-obesity treatment.

Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...

The regulatory agency will review MSD’s new drug application (NDA) for Welireg under a Priority Review, with a Prescription ...

With continued investment and growing buzz from the industry, the AI hype is expected to extend through 2025 and beyond.